Pumitamig for Advanced or unresectable hepatocellular carcinoma (a type of liver cancer) as first-line treatment
Bristol-Myers Squibb· ROSETTA HCC-206
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT07291076 on ClinicalTrials.gov →Study type
interventional
Design
Open-label, randomized, parall…
Target enrollment
198
Est. completion
2029-10-15
Investor scorecard
Probability of success
low
Timeline to catalyst
Initial safety data may be available in 2027, with efficacy data (ORR) possibly in 2028. The trial is expected to complete in 2029.
Potential stock impact
ModeratePhase 1/2 trials in oncology have a low probability of success, typically around 10-20% for advancing to approval. The trial is early, and safety and efficacy are unknown. However, the combination with ipilimumab is based on a known mechanism, and BMS has experience with immunotherapies, which might slightly increase the chances. But given the competitive landscape with multiple approved first-line options, the bar for success is high.
What is being tested?
This trial is testing a new drug called pumitamig, alone or combined with another drug called ipilimumab, for patients with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery. Pumitamig is a type of immunotherapy that helps the immune system attack cancer cells. Ipilimumab is another immunotherapy that blocks a protein called CTLA-4, which can slow down immune responses. The goal is to see if the combination is safe and effective as a first-line treatment, meaning it's given before any other cancer therapy.
How does the trial work?
The trial is open-label, meaning both doctors and patients know which treatment they receive. It's randomized, so patients are assigned by chance to receive either pumitamig alone or pumitamig plus ipilimumab. It's a phase 1/2 trial, so it first tests safety and dosing, then expands to look at how well it works. About 198 patients will be enrolled. They will receive the treatment in cycles, and doctors will monitor them for side effects and tumor response using imaging scans. The trial is expected to start in March 2026 and run until October 2029.
What does success look like?
Success would be shown if the treatment is safe enough (with manageable side effects) and if it shrinks tumors in a meaningful number of patients. The primary measure of effectiveness is the objective response rate (ORR), which is the percentage of patients whose tumors shrink or disappear. For liver cancer, an ORR of around 20-30% would be considered promising, especially if responses are durable. The trial will also look at how long patients live without the cancer progressing (progression-free survival) and overall survival, though these are not primary endpoints in this early phase.
What it means for investors
For investors, this trial is an early-stage test of a new combination. Positive safety and efficacy data could boost Bristol-Myers Squibb's pipeline and stock, especially if it shows a competitive edge over existing treatments like lenvatinib or sorafenib. However, phase 1/2 trials have a high failure rate, so the stock impact may be limited until later-phase data. If the trial is successful, it could lead to a larger phase 3 trial, which would be a major catalyst. If it fails, it might not significantly hurt BMS because they have other drugs, but it could dampen enthusiasm for pumitamig. Investors should watch for safety signals and early efficacy readouts, which could come in 2027-2028.
Trial endpoints
Primary endpoints
Secondary endpoints
Comparator
Pumitamig alone vs. Pumitamig plus ipilimumab (no placebo)
Competitive landscape
Liver cancer is a significant global health issue, with over 900,000 new cases each year. Hepatocellular carcinoma (HCC) is the most common type, and many patients are diagnosed at an advanced stage where surgery isn't possible. The first-line treatment market for advanced HCC is growing, with several approved therapies. The global market for HCC treatments is expected to reach several billion dollars by 2030. If pumitamig, a novel bispecific antibody, shows promise, it could capture a share of this market, especially if it offers better efficacy or safety than existing options.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Atezolizumab + bevacizumab (Tecentriq + Avastin) | Roche | Phase 1 | Already approved for first-line HCC, combines PD-L1 inhibitor with anti-VEGF antibody. |
| Durvalumab + tremelimumab (Imjudo + Imfinzi) | AstraZeneca | Phase 1 | Approved for first-line HCC, combines PD-L1 and CTLA-4 inhibitors. |
| Pembrolizumab (Keytruda) | Merck | Phase 1 | PD-1 inhibitor being tested in combination with lenvatinib for first-line HCC. |
| Nivolumab + ipilimumab (Opdivo + Yervoy) | Bristol-Myers Squibb | Phase 1 | Approved for second-line HCC, but not first-line; this trial tests pumitamig with ipilimumab in first-line. |
Historical context
Prior trial results
Pumitamig is an investigational drug, and this is likely its first trial in HCC. It may have been studied in other cancers, but no prior results are publicly available. Ipilimumab is already approved for various cancers, including melanoma and HCC in combination with nivolumab.
Regulatory history
No regulatory designations (like fast track or breakthrough) have been announced for this trial. Ipilimumab has a long history, including a boxed warning for immune-related adverse events.
Similar drug precedents
Bispecific antibodies like pumitamig have shown promise in other cancers, but none have been approved for HCC yet. The combination of PD-1 and CTLA-4 inhibitors has been successful in HCC, as seen with nivolumab plus ipilimumab, which is approved for second-line. This trial aims to move that concept to first-line with a novel bispecific.